澄實生物致力于利用人工智能與 mRNA 技術(shù)平臺,開發(fā)針對腫瘤和傳染病的創(chuàng)新療法與疫苗,讓更多患者獲得前沿治療。
TheraRNA leverages AI and mRNA technology platforms to develop innovative therapies and vaccines targeting cancer and infectious diseases.
了解核心技術(shù) Explore our technology我們相信,人工智能與免疫學(xué)的深度融合將徹底改變藥物研發(fā)的范式。從 AI 新生抗原預(yù)測到自研 LNP 遞送系統(tǒng),從 mRNA 分子設(shè)計到 GMP 規(guī)模化量產(chǎn)——澄實生物構(gòu)建了全鏈條自主可控的技術(shù)閉環(huán),打通從算法到產(chǎn)品的完整路徑。
We believe the deep integration of artificial intelligence and immunology will fundamentally transform drug development. From AI neoantigen prediction to proprietary LNP delivery systems, from mRNA molecular design to GMP mass production — TheraRNA has built a fully self-controlled technology closed loop, bridging algorithm to product.
了解更多 Read more

基于 AI 新生抗原預(yù)測的個性化腫瘤 mRNA 疫苗,聯(lián)合多家三甲醫(yī)院開展 IIT 臨床研究,客觀緩解率達(dá) 67%。
Individualized mRNA cancer vaccines based on AI neoantigen prediction, with IIT clinical studies at top hospitals achieving 67% ORR.
了解管線Learn more
全球首創(chuàng)耐藥細(xì)菌 mRNA 疫苗管線,金黃色葡萄球菌 mRNA 疫苗已完成多輪動物實驗驗證,攻克免疫印記難題。
World's first anti-drug-resistant bacteria mRNA vaccine pipeline. S. aureus vaccine validated in multiple animal studies, overcoming immune imprinting.
了解管線Learn more
動保反哺人用,以定制化 mRNA 動物疫苗快速驗證技術(shù)路徑,覆蓋貓狗絕育、弓形蟲、寵物腫瘤等藍(lán)海品種。
Veterinary products validating human therapeutics. Customized mRNA animal vaccines covering sterilization, toxoplasmosis, and pet oncology.
了解管線Learn more利用 mRNA 技術(shù)平臺的強(qiáng)大通用性和 AI 算法的高效迭代能力,構(gòu)建覆蓋多適應(yīng)癥的豐富管線。
Leveraging the versatility of mRNA platforms and AI-driven rapid iteration to build a diversified pipeline across multiple indications.